MetroHealth completed its vector and cellular Good Manufacturing Practice facility that will enable quick, reliable production and processing of the latest cellular immunotherapies, including CAR T-cell and tumor-infiltrating lymphocytes cancer therapies.
To access this subscriber-only content please log in or subscribe.
If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.
Login Subscribe
If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.
Login Subscribe